SphingoTec Appoints Dr. Florian Uhle as Medical Director
Hennigsdorf/Berlin, Germany, February 23, 2023
– Diagnostic company SphingoTec is pleased to announce the appointment of Dr. Florian Uhle as the company's new Medical Director. Dr. Uhle is a subject matter expert in translating innovations into routine clinical practice with a broad experience in both clinical and corporate settings.
Dr. Uhle brings a wealth of knowledge and experience to the role, having spent 15 years in healthcare. In his new position, he will work cross-functionally to perfect the clear applications of the company's innovative diagnostic biomarkers while focusing on expanding their use for added value in clinical practice. SphingoTec recognizes the importance of addressing unmet needs in critical care settings with clear applications that can improve decision-making and patient management while reducing healthcare cost.
Jörg Menten, Managing Director and CEO of SphingoTec, comments, "We are thrilled to welcome Dr. Uhle to our team as our new Medical Director. His experience in the medical field and passion for innovation make him the perfect candidate for this role. He will support our goal of increasing awareness and demand for our biomarker-based diagnostic innovations within the acute and critical care community."
Dr. Florian Uhle said, "I am excited to join SphingoTec and work with such a talented and innovative team. The company's diagnostic portfolio has the potential to meet the growing need for effective diagnostic tools in critical care settings. I am eager to apply my knowledge and expertise to help bring the company's biomarkers to the forefront of clinical practice and to work towards improving patient outcomes."
Before joining SphingoTec, Florian Uhle, Ph.D., was Director of Medical Affairs at Inflammatix Inc., a development-stage diagnostic company focusing on acute and critically ill patients. Prior to that, he held several leadership roles within the University Hospitals Heidelberg and Giessen, focusing on leading diagnostic research activities and innovation-oriented initiatives. He has a diploma in Biology from the Justus-Liebig University, a Master of Science from the University of Leipzig in Clinical Research and Translational Medicine, and a Ph.D. in Human Biology from the Justus-Liebig University. He completed the International Graduate School „Molecular Biology and Medicine of the Lung“ at the Universities of Giessen and Marburg Lung Center.
About SphingoTec
SphingoTec GmbH ("SphingoTec"; Hennigsdorf near Berlin, Germany) is a commercial-stage diagnostic company focusing on innovative critical care biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. SphingoTec’s innovative markers are made available on different IVD platforms. SphingoTec's proprietary biomarker portfolio includes Proenkephalin A 119-159 (penKid), a biomarker for the assessment of kidney function in critical diseases, and bioactive Adrenomedullin 1-52 (bio-ADM), a biomarker for the assessment of endothelial function in conditions like sepsis.
Media contact:
Ruxandra Lenz
Head of Marketing and Communication
SphingoTec GmbH
Neuendorfstr. 15 A
16761 Hennigsdorf
Tel. +49-3302-20565-0
Hennigsdorf, Germany, 23 July 2026 — SphingoTec GmbH announces that its Chief Executive Officer, Deborah Bergmann, will attend the ADLM 2026 Annual Meeting, taking place from July 26 to 30, 2026. During the conference, SphingoTec will engage with current and prospective partners to discuss ongoing collaborations and opportunities to advance innovations in critical care diagnostics. These interactions support SphingoTec’s strategy to expand the clinical and commercial reach of its biomarker portfolio. “ADLM provides an important platform to connect with partners across the diagnostics ecosystem,” said Deborah Bergmann, CEO of SphingoTec. “These discussions align with our commitment to translating biomarker innovation into clinically meaningful solutions for patients in critical care.” About SphingoTec SphingoTec GmbH ("SphingoTec"; Hennigsdorf near Berlin, Germany) is a biomarker company focusing on the out-licensing of innovative critical care solutions for diagnosing, predicting, and monitoring acute medical conditions. SphingoTec develops its biomarkers to the commercial stage and partners with IVD companies to make them available on different IVD platforms. SphingoTec's proprietary biomarker portfolio includes Proenkephalin A 119-159 (penKid), a biomarker for the assessment of kidney function in critical diseases, and bioactive Adrenomedullin 1-52 (bio-ADM), a biomarker for the assessment of endothelial function in conditions like sepsis. Discover more on www.sphingotec.com Media Contact: Email: press@sphingotec.com Phone +49-3302-20565-0 SphingoTec GmbH Neuendorfstr. 15A 16761 Hennigsdorf, Germany
• New ELISA sphingotest® penKid® enables widespread measurement of the kidney function biomarker Proenkephalin 119-159 (penKid) using standard laboratory equipment. • Only available test to match SphingoTec’s reference chemiluminescence assay, developed with patented high-sensitivity technology to provide consistent results across platforms. Hennigsdorf/Berlin, Germany, April 28 2026 - SphingoTec GmbH announces the launch of the ELISA sphingotest® penKid®, a new assay designed to make testing of its proprietary biomarker broadly accessible to research laboratories and pharmaceutical partners. Providing ease-of-use and precision, the test facilitates large-scale investigations of human kidney function in both acute and broader clinical research contexts. Responding to growing research interest The launch follows increasing demand from the scientific community to study penKid - a biomarker reflecting the current state of kidney function in critical care environments. While SphingoTec’s high-sensitivity sphingotest® penKid® assay serves as the reference method for clinical research and third-party IVD assays, the assay technology requiring dedicated equipment was not easily adoptable in research laboratories. The new ELISA sphingotest® penKid® now allows researchers worldwide to benefit from SphingoTec’s patented detection technology using standard photometers, extending penKid testing capability to a wider range of laboratories. Proven performance and data continuity The ELISA sphingotest® penKid® has been developed to achieve excellent correlation with SphingoTec’s reference chemiluminescence assay, ensuring consistent, high-quality results across different assay platforms. Both methods share the same underlying technology capable of detecting penKid concentrations in the picomolar range. Thanks to this technology transfer, researchers can rely on the same analytical precision and reliability that supported the clinical studies establishing penKid as a valuable kidney function biomarker. The assay’s robust design and German manufacturing ensure durable consistency and reproducibility. With this research-use ELISA, SphingoTec responds to the increasing availability of non-validated assays and encourages researchers to not compromise assay quality and performance to ensure trustworthy results - since data from non-validated tests may reflect assay limitations rather than the true performance of the penKid biomarker. Complementary approaches for clinical use and scientific exploration SphingoTec pursues its commercial strategy for the biomarker penKid through strategic out-licensing partnerships such as Boditech Med, which has developed an IVDR-certified assay for routine clinical use and rapid diagnostics. The newly launched ELISA sphingotest® penKid® represents a complementary initiative, specifically designed to support high-throughput clinical and translational research. Through this dual approach, SphingoTec reaffirms its commitment to fostering scientific collaboration and promoting the broader exploration of penKid across diverse research settings. “Developing the ELISA sphingotest® penKid® reflects our long-term commitment to improving critical care diagnostics,” said Deborah Bergmann, Managing Director and CEO of SphingoTec GmbH. “Beyond its currently validated clinical applications, we see strong potential for penKid to support research and improve diagnostics in other fields where kidney function is relevant. By encouraging scientists worldwide to incorporate penKid into their studies and clinical programs, we aim to accelerate innovation and advance best-fit diagnostic solutions that ultimately improve patient care.” About SphingoTec SphingoTec GmbH ("SphingoTec"; Hennigsdorf near Berlin, Germany) is a biomarker company focusing on the out-licensing of innovative critical care solutions for diagnosing, predicting, and monitoring acute medical conditions. SphingoTec develops its biomarkers to the commercial stage and partners with IVD companies to make them available on different IVD platforms. SphingoTec's proprietary biomarker portfolio includes Proenkephalin A 119-159 (penKid), a biomarker for the assessment of kidney function in critical diseases, and bioactive Adrenomedullin 1-52 (bio-ADM), a biomarker for the assessment of endothelial function in conditions like sepsis. Discover more on www.sphingotec.com Media Contact: Email: press@sphingotec.com Phone +49-3302-20565-0 SphingoTec GmbH Neuendorfstr. 15A 16761 Hennigsdorf, Germany